Ann: HER-Vaxx superior to Herceptin in tumour model, page-3

Dear Shareholders
I have pleasure in providing this update on developments at Imugene.
This update covers many topics, but for the first time we have included data concerning an anti tumour in vitro experiment that studied the effects on a particular tumour cell line of antibodies developed by HER-Vaxx versus Herceptin.
While this is just one study, we have reproduced this data to remind investors of our optimism not only in HER-Vaxx, but especially in the new formulation of HER-Vaxx as recently announced. HER-Vaxx Data – Improved Growth Inhibition of Breast Cancer Cells Compared with Herceptin®
• Improved inhibition at comparable dose of Herceptin®
• Identical inhibition at one third dose compared with Herceptin®
• Highly statistically significant result (P<0.001)
• Data supports optimism that HER-Vaxx produces antibodies potentially superior to Herceptin®

HER-Vaxx demonstrated an improved growth inhibition on the human breast cancer cell line SKBR-3 compared with the currently prescribed gold standard antibody Herceptin® (Trastuzamab). Herceptin® recorded sales for pharma giant Roche of US$6.4 billion in 2014.


HER-Vaxx stimulates a polyclonal antibody response to HER-2/neu, the same oncogene that is targeted by Herceptin®.